In the present study, even if our results are limited to the techniques used with their analytic sensitivity and complexity, we reported a high level of concordance between plasma and tumor BRAF mutation status in mCRC patients, especially those with liver metastases. The gene discussed is BRAF; the disease is neoplasm.